ABSTRACT
Background Low Back Pain (LBP) is a long-term health condition with distinct clinical courses. The characterization of these courses together with the identification of prognostic factors of a persistent disabling LBP course has the potential to enable a better identification of patients in high-risk and ultimately allow the development of personalized interventions to change their long-term prognosis. This study aimed to assess the course of chronic LBP (CLBP) over 5 years in a large population-based study, its cumulative impact on disability and health-related quality of life (HRQoL) and the indicators for persistent CLBP course.
Material and methods Active CLBP participants were identified from a representative sample of 10.661 adults randomly recruited from the dwelling population of EpiDoC. Pain, disability and HRQoL were assessed at three time-points. According to their pain symptoms over time, participants were classified as having a persistent or relapsing pain course. A General Linear Model was used to compare mean differences between and within groups. The relation between baseline variables and persistent CLBP was modulated through logistic regression.
Results Among the 1.201 adults with active CLBP at baseline, 634 completed the three time-points of data collection (52.8%) and 400 (63.1%) were classified as having a persistent course. Statistically significant interactions were found between the group and time on disability (F (2.126)= 23.78, p<0.001) and HRQoL (F (2.125)= 82.78, p<0.001). In the adjusted model, the persistent course was associated with the disability level (OR: 1.84, CI95% 1.4 to 2.4), presence of depressive symptoms (OR: 1.96, CI95% 1.2 to 3.2), female gender (OR: 1.9, CI95% 1.26-2.87), and having a manual job (OR: 1.46, CI95% 1.02 to 2.1).
Conclusion In the long-term, CLBP patients have distinct clinical courses. Being female, presenting depressive symptoms, having a manual job and a higher disability at baseline predict a CLBP persistent outcome.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
"N/A"
Funding Statement
The work presented in this paper is associated to a research project financed by the Portuguese Science & Technology Foundation (PTDC/SAU-SER/7406/2020), awarded by Eduardo Brazete Cruz. The corresponding author, Luís Antunes Gomes, is supported by an individual PhD grant (SFRH/BD/145636/2019) of the same institution. Portuguese Science & Technology Foundation website: https://www.fct.pt/ EpiReumaPt was supported by unrestricted grants from Direção-Geral da Saúde, Fundação Calouste Gulbenkian, Fundação Champalimaud, Fundação AstraZeneca, Abbvie, Merck, Sharp & Dohme, Pfizer, Roche, Servier, Bial, D3A Medical Systems, Happybrands, Center de Medicina Laboratorial, Germano de Sousa, Clínica Médica da Praia da Vitória, CAL-Clínica, Galp Energia, Açoreana Seguros, and individual rheumatologists. Data were provided by the EpiDoc Unit - CEDOC with permission. Funders did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The EpiReumaPt study was approved by the Ethics Committee of NOVA Medical School (ID of ethics approval: #CEFCM_07/2011) and the Portuguese Data Protection Authority (ID of ethics approval: 7439/2011). All participants gave written informed consent in accordance with principles established by the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
